Photo: Courtesy of Teva
3 August 2016Americas
Teva completes acquisition of Allergan generics business
Teva’s acquisition of Allergan’s generic business (Actavis Generics) has been completed, the company revealed yesterday.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
28 July 2016 Teva announced yesterday that the Federal Trade Commission has accepted its proposed $40.5 billion buyout of Allergan’s generics business after the Isreal-based company agreed to sell nearly 80 products to address competition concerns.
Editor's picks
Editor's picks
Americas
28 July 2016 Teva announced yesterday that the Federal Trade Commission has accepted its proposed $40.5 billion buyout of Allergan’s generics business after the Isreal-based company agreed to sell nearly 80 products to address competition concerns.
Americas
28 July 2016 Teva announced yesterday that the Federal Trade Commission has accepted its proposed $40.5 billion buyout of Allergan’s generics business after the Isreal-based company agreed to sell nearly 80 products to address competition concerns.